non-cystic fibrosis bronchiectasis

News

FDA, bronchiectasis and Cystic Fibrosis

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a first-in-class reversible DPP-1 inhibitor, it targets the

· 3d · on MSN

First drug to treat bronchiectasis lung condition approved by FDA

Clinical Advisor · 2d

Brinsupri Approved for Non-Cystic Fibrosis Bronchiectasis

Stocktwits on MSN3d

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

Monthly Prescribing Reference13y

Azithromycin Treats Non-Cystic Fibrosis Bronchiectasis

Conroy Wong, MB, ChB, from Middlemore Hospital in Auckland, New Zealand, and colleagues conducted a randomized trial involving patients with non-cystic fibrosis bronchiectasis. Participants, who ...

Pharmaceutical Technology4d

Fosun and Expedition make $645m licensing deal for respiratory drug

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results